William Aronson is a Genitourinary physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 570 publications with 19,040 citations (h-index 70); ClinicalTrials.gov lists 5 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Urology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- PSMA PET Scan and mpMRI for Prostate Cancer Detection
Sponsor: VA Greater Los Angeles Healthcare System
- Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
Sponsor: Jonsson Comprehensive Cancer Center
- Low-Fat Fish Oil Diet for Prostate Cancer Prevention
Sponsor: Jonsson Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
35 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
NIH funding
3 NIH research awards on record, funded 2002–2022 per NIH RePORTER. The latest:
- Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
University of California Los Angeles
FY2022$422,350R01CA231219 - Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
University of California Los Angeles
FY2021$430,969R01CA231219 - Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
University of California Los Angeles
FY2020$430,969R01CA231219
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Prostate Cancer and Prostatic Diseases
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Raj Makkar, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
Cristina Ferrone, MD
Cedars-Sinai Medical Center
Stephen Pandol, MD
Cedars-Sinai Medical Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”